[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oag---open-angle-glaucoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oag---open-angle-glaucoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100620199","phase-2-study-of-qls-111-fdc-in-open-angle-glaucoma-or-ocular-hypertension-100620199",false,"NCT07354516","Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension","A Masked, Randomized, Prospective Study of QLS-111-FDC in Subjects With Open-Angle Glaucoma or Ocular Hypertension","Firecrest","Inclusion Criteria:\n\n* BCVA 1.0 logMAR or better in each eye (equivalent to 20\u002F200)\n* Diagnosis of mild to moderate OAG or OHT in at least one eye\n* IOP ≥19 mmHg at 08:00 hour (H) at Qualification Visits following a run-in with PF latanoprost\n\nExclusion Criteria:\n\n* History of active ocular disease other than mild to moderate OAG\u002FOHT\n* Prior use of any topical PGA without a clinically meaningful response\n* Noncompliant with current ocular anti-hypertensive medications or unwilling to be compliant throughout the study\n* Use of other topical ocular concomitant medications 30 days prior\n* History of angle closure or a narrow angle, significant ocular trauma, ocular infection, uveitis, intraocular surgery in either eye.\n* Central corneal thickness in either eye \\\u003C470 or \\>630 μm\n* Clinically significant systemic or psychiatric disease, chronic kidney disease, or hypertension, hypotension, or diabetes that is uncontrolled.\n* Participation in any investigational study within 30 days prior to Screening\n* Females who are pregnant, nursing, or not using birth control.","ALL","12 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free \\[PF\\], fixed-dose combination \\[FDC\\] investigational product (IP) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).",[28,29],"OAG - Open-Angle Glaucoma","OHT - Ocular Hypertension",[31,32,33],"glaucoma","intraocular pressure (IOP)","eye drops","RECRUITING","2026-03-30",{"date":37,"type":38},"2026-04-03","ACTUAL",{"date":40,"type":38},"2026-03-18",{"date":42,"type":21},"2026-07-15",{"name":44,"class":45},"Qlaris Bio, Inc.","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100492777","clinical-trial-to-evaluate-the-safety-and-effectiveness-of-a-canaloplasty-device-in-subjects-with-open-angle-glaucoma-100492777","NCT05696561","Clinical Trial to Evaluate the Safety and Effectiveness of a Canaloplasty Device in Subjects With Open-Angle Glaucoma","A Prospective, Multicenter, First in Human Clinical Trial to Evaluate the Safety and Effectiveness of the DF12 CANALOPLASTY AND TRABECULOTOMY SURGICAL SYSTEM in Subjects With Open-Angle Glaucoma Undergoing Cataract Surgery","Inclusion Criteria:\n\n1. Subjects qualifying for cataract surgery\n2. Subjects with diagnosis of open-angle glaucoma in at least one eye with unmedicated IOP of 22-34 mmHg.\n\nExclusion Criteria:\n\n1\\. Patients who cannot be washed-out of IOP-lowering medications.","22 Years",{"count":56,"type":21},70,[58],"NA","Clinical Trial to Evaluate the Safety and Effectiveness of a Canaloplasty Device in Subjects with Open-Angle Glaucoma",[28],"2026-02-24",{"date":63,"type":38},"2026-02-27",{"date":65,"type":38},"2025-09-09",{"date":67,"type":21},"2027-10",{"name":69,"class":45},"New World Medical, Inc.",3]